Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZM2L1
|
|||
| Drug Name |
AFM13
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hodgkin lymphoma [ICD-11: 2B30; ICD-10: C81, C81.9] | Phase 2 | [1] | |
| Mycosis fungoides [ICD-11: 2B01; ICD-10: C84.0] | Phase 2 | [2] | ||
| Peripheral T-cell lymphoma [ICD-11: 2A90.C; ICD-10: C84.4; ICD-9: 202.7] | Phase 2 | [2] | ||
| Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1/2 | [3] | ||
| Company |
Affimed Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immunoglobulin gamma Fc receptor IIIA (FCGR3A) | Target Info | . | [4] |
| Lymphocyte activation antigen CD30 (TNFRSF8) | Target Info | . | [4] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02321592) GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04101331) Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of Affimed Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.